[Arterial infusion of combination therapy using dibutyryl adenosine 3',5'-monophosphate and mitomycin C for nodular type of hepatocellular carcinoma non-occluding the main portal vein--in comparison with transcatheter arterial embolization].
Seventy five patients with nodular type of hepatocellular carcinoma (HCC) non-occluding the main portal vein were divided into the following groups and were compared for the prognosis: (I) administered intraarterial infusion therapy combining dibutyryl adenosine 3',5'-monophosphate (DBcAMP) and mitomycin C (MMC) (n = 13); (II) treated with transcatheter arterial embolization (TAE) (n = 62). No marked difference was observed between two groups before treatment concerning the tumor size and the underlying clinical state confirmed by Child's method. Fifty % survival disclosed to be 21 months in both groups, whereas viewed from the tumor type of being single or multi-nodular, the median survival was as follows: 14 months (n = 6) and 21 months (n = 7) in group I, and 30 months (n = 25) and 20 months (n = 37) in group II, respectively. However, combination therapy exerted a reduced frequency of patients succumbing within one year after treatment: 1 (7.7%) as compared to 16 (25.8%) in group II. It is concluded that combination therapy with DBcAMP and MMC has an almost same salutary effect as TAE on HCC non-occluding the main portal vein.
Sugimoto
M
M
Division of Clinical Pharmacology, Kitasato University East Hospital.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003994:Bucladesine / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D011169:Portal Vein; D015996:Survival Rate
D016685:Mitomycin; D003994:Bucladesine